Erschienen in:
01.12.2014 | Prevention of Heart Failure (M St. John Sutton, Section Editor)
Cancer and Cardiovascular Disease: the Use of Novel Echocardiography Measures to Predict Subsequent Cardiotoxicity in Breast Cancer Treated with Anthracyclines and Trastuzumab
verfasst von:
Gaurav Gulati, Kathleen W. Zhang, Marielle Scherrer-Crosbie, Bonnie Ky
Erschienen in:
Current Heart Failure Reports
|
Ausgabe 4/2014
Einloggen, um Zugang zu erhalten
Abstract
As the population of breast cancer survivors grows, it has become evident that chemotherapy has significant cardiotoxic side effects. Echocardiography is a noninvasive, cost-effective, and widely available imaging tool that is well positioned to serve as a primary modality for monitoring chemotherapy-induced cardiotoxicity. Although left ventricular ejection fraction is a standard measurement by which to monitor chemotherapy-induced cardiotoxicity, its predictive value in identifying subsequent cardiotoxicity is limited. More sophisticated echocardiography modalities may offer improved sensitivity and specificity for detecting chemotherapy-induced cardiotoxicity. These include tissue Doppler imaging measures, newer techniques based upon two- and three-dimensional strain and torsion analysis, and three-dimensional measures of cardiac size. While these modalities are not all currently part of clinical practice, a body of data supporting their use is steadily building. More research remains to be performed, and noninvasively detecting cancer therapy-induced cardiac dysfunction at the earliest stages is of increasing interest.